Introduction {#s1}
============

Schizophrenia is a serious psychiatric disorder of unknown etiology. The disorder is thought to be the product of genetic and environmental interactions consistent with involvement of the immune system. Genome-wide-association-studies point to schizophrenia risk loci in the major-histocompatibility-complex region of chromosome 6 where many immune-related genes are located ([@B1]). A susceptibility locus for schizophrenia, complement C4, is of interest since it is a component of the immune system and is also involved in synaptic pruning in the brain ([@B2], [@B3]). Environmental and epidemiological studies indicate that people with schizophrenia have increased rates of exposure to pathogens and other antigens ([@B4], [@B5]). A reported phenotype in these individuals is a pervasive low level inflammation of unknown origin ([@B6], [@B7]).

Immune system homeostasis is principally established and regulated by the GI mucosa and its community of resident microbiota ([@B8], [@B9]). When this balance is upset, for example by stress, toxins, infections, antibiotics or genetic susceptibility, a toxic cycle of inflammation, microbial translocation and dysbioses ensue. In the literature of schizophrenia, there is a long history that GI disturbances are part of the pathophysiology of this disorder, with many disturbances inflammatory in nature. Related reports predate the advent of modern antipsychotics, suggesting that this GI inflammation is not simply the result of cholinergic effects from agents such as clozapine ([@B10]).

The endocrine system is another postulated source for the chronic inflammation associated with schizophrenia. Especially implicated are certain conditions including metabolic syndrome, obesity, and diabetes as well as basic differences in disease pathophysiology between males and females ([@B11]--[@B13]). These conditions are often the result of antipsychotics that slow metabolism and contribute to weight gain and a disrupted metabolic state. Metabolic syndrome may occur in up to 50% of people with schizophrenia either through a direct modulation of insulin-associated tissue, glucose metabolism or increased production of adipose tissue ([@B14]). Another endocrine-based candidate is the end product of the hypothalamus--pituitary-axis (HPA), the stress hormone, cortisol. Alterations of the cortisol awakening response is a proposed risk factor for the development of schizophrenia ([@B15]).

Research on schizophrenia and other psychiatric disorders has begun to focus on organ systems outside of the brain to determine if mechanisms involved in the periphery and as part of a whole-body approach might offer fresh perspectives and insight regarding disease etiology and treatment. Given the high prevalence of these comorbid conditions and the pervasive inflammatory phenotype in schizophrenia, we undertook to ascertain the relative contributions of GI and endocrine disturbances to the inflammatory pathophysiology of schizophrenia. There is currently uncertainty regarding how these conditions are related to each other and to what degree each may be the source of inflammation in schizophrenia. Thus, further complicating this issue is the uncertainty regarding the specificity of serum or plasma biomarkers as proxies for GI and endocrine levels of inflammation. Blood biomarkers typically used to measure gut-derived microbial translocation include LBP and sCD14, but the specificity of these markers for GI processes have been questioned ([@B16], [@B17]). Another biomarker of microbial translocation, antibodies directed against *S. cerevisiae*, is one component of a serological panel used clinically to diagnose the inflammatory bowel disorder, Crohn's disease ([@B18]--[@B20]). Similarly, antibodies against food-derived proteins such as wheat gluten and milk casein are used to diagnose food antigen sensitivities and for wheat gluten, a clinical diagnosis of Celiac disease ([@B21], [@B22]). In this study, we review data from individuals with schizophrenia who had reported or had in their medical record information about the presence of GI or endocrine conditions comorbid with their psychiatric disorder. We measured plasma levels of systemic inflammation using CRP and compared these to measures of presumably GI-related biomarkers in individuals with schizophrenia with and without GI or endocrine disorders.

Materials and Methods {#s2}
=====================

Study Population {#s2_1}
----------------

Study participants were recruited at Sheppard Pratt Health System located in Baltimore, MD, U.S.A. as part of an ongoing schizophrenia cohort. We reviewed the study database to include individuals with schizophrenia for whom we had information regarding the presence or absence of GI and endocrine conditions. The original collection of this information was carried out as a standard assessment in our studies. A total of 409 individuals with schizophrenia were identified. These individuals were stratified into four groups: (1) GI negative and endocrine negative (GI−/endocrine−); (2) GI positive and endocrine negative (GI+/endocrine−); (3) GI negative and endocrine positive (GI−/endocrine+); (4) GI positive and endocrine positive (GI+/endocrine+). The classification of conditions was done systematically by review of medical records and patient interviews performed by the research nurse. Conditions queried were based on past studies indicating their presence in the population of individuals which compose the study groups. As part of the research assessment, participants were queried about the presence or absence of specific disorders which were organized by body system, as described previously ([@B23]). GI conditions included constipation, Crohn's disease, diarrhea, diverticulitis, GI bleeding, gastritis, GERD, irritable bowel syndrome, lactose intolerance, stomach cancer, surgical GI procedures, and ulcers. Endocrine conditions included Diabetes Mellitus (Type I and Type II), glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency, gynecomastia, hyperglycemia, hypernatremia, obesity, premenstrual dysphoric disorder, rhabdomyolysis, and thyroid problems. The prevalence of GI and endocrine conditions is listed in [**Table 1**](#T1){ref-type="table"}. For statistical comparisons described below, the comparison control group includes those individuals with schizophrenia who were GI−/endocrine−.

###### 

Prevalence of comorbid GI and endocrine conditions.

                                                               n     \%
  ------------------------------------------------------------ ----- --------
  **Gastrointestinal**                                               
  Constipation                                                 86    29.55%
  Crohn's Disease                                              1     0.34%
  Diarrhea                                                     26    8.93%
  Diverticulitis                                               3     1.03%
  GI bleeding                                                  1     0.34%
  Gastritis                                                    6     2.06%
  GERD/acid reflux                                             120   41.24%
  Irritable bowel syndrome                                     7     2.41%
  Lactose intolerance                                          3     1.03%
  Stomach cancer                                               2     0.69%
  Surgical GI procedures                                       22    7.56%
  Ulcers                                                       14    4.81%
                                                                     
  **Endocrine**                                                      
  Diabetes                                                     63    23.60%
  Glucose-6-Phosphate Dehydrogenase (G6PD) Enzyme Deficiency   7     2.62%
  Gynecomastia                                                 2     0.75%
  Hyperglycemia                                                2     0.75%
  Hypernatremia                                                1     0.37%
  Obesity                                                      155   58.05%
  Premenstrual Dysphoric Disorder                              3     1.12%
  Rhabdomyolysis                                               1     0.37%
  Thyroid problems                                             33    12.36%

Diagnostic methods were described previously ([@B24], [@B25]). Individuals received DSM-IV-TR diagnoses of schizophrenia, schizophreniform disorder, or schizoaffective disorder ([@B26]). Individuals were between the ages of 18 and 65. Cognitive functioning was evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Form A ([@B27]) and psychiatric symptoms rated with the Positive and Negative Syndrome Scale (PANSS) ([@B28]).

These studies were approved by the Institutional Review Boards (IRB) of the Sheppard Pratt Health System and the Johns Hopkins Medical Institution following established guidelines. All participants provided written informed consent after study procedures were explained. This research was performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Biomarker Data {#s2_2}
--------------

For all participants, a blood sample was drawn from which were measured CRP, LBP, sCD14, *Saccharomyces cerevisiae* IgG, bovine milk casein IgG, and wheat gluten IgG. Biomarker positivity was defined based on quantitative levels of these markers in healthy controls. Biomarker values in the schizophrenia population which exceeded the 90th percentile of healthy control values were considered seropositive. Individuals who were considered healthy controls were those without a history of psychiatric disorder based on interviews carried out with the Structured Clinical Interview for DSM-IV Axis I Disorders Non-Patient Edition ([@B29]). Methods and analyses reporting psychiatric case and control levels and cut-off seropositivity values of these biomarkers were previously described ([@B25], [@B30]--[@B34]). In brief, exclusion criteria for both cases and controls included: mental retardation; clinically significant medical disorder that would affect cognitive performance; any history of intravenous substance abuse or a primary diagnosis of substance abuse or substance dependence. Active substance misuse was considered an additional exclusion criterion for controls. Comorbid GI and endocrine conditions were not exclusion criteria for cases or controls. The healthy control group was composed of 311 individuals of mean age 32+/−0.63 years, 61.09% female and were 64.31% Caucasian.

Data Analyses {#s2_3}
-------------

Chi-square analyses were used to detect significant differences in categorical variables among comorbidity groups. ANOVAs with *post-hoc* Sidak analyses and t-tests were used to identify mean differences between groups for continuous variables. Multivariate logistic regression models were used to assign odds ratios for biomarker positivity associations with GI/endocrine groups and to evaluate the interaction between GI and endocrine variables. All multivariate analyses included the covariates of age, sex, race, cigarette smoking, and maternal education as a proxy for socioeconomic status. P-values of \<0.05 are listed; however, Bonferroni correction of multiple comparisons would designate more robust associations for those p-values that are \<0.008.

Results {#s3}
=======

Characteristics of the Study Population {#s3_1}
---------------------------------------

As described in the *Methods*, participants in this study were divided into four groups according to whether or not a comorbid GI or endocrine condition was present. The characteristics of these groups are shown in [**Table 2**](#T2){ref-type="table"}. GI conditions were present in 58.1% females and 48.7% males, and endocrine conditions were present in 64.2% females and 50.6% males. Females were more likely to have both GI and endocrine disturbances, whereas males were more likely to have neither (chi-square = 9.19, p \< 0.03). Participants with both GI and endocrine disturbances also were older than those who had neither type of condition (ANOVA, F = 5.00, p \< 0.001). There were no significant differences between the four GI and endocrine groups in terms of race, maternal education, cigarette smoking or current antipsychotic, anticholinergic or antibiotic medications ([**Table 2**](#T2){ref-type="table"}).

###### 

Characteristics of the sample by GI and endocrine comorbidity status.

  -------------------------------------------------------------------------------------------------------
                                 GI−/Endoc−^1^   GI+/Endoc−     GI−/Endoc+     GI+/Endoc+        Total
  ------------------------------ --------------- -------------- -------------- ----------------- --------
  All                            107 (26.16)     75 (18.34)     89 (21.76)     138 (33.74)       409

  Female                         27 (18.24)      26 (17.57)     35 (23.65)     60 (40.54)^2^     148

  Male                           80 (30.65)      49 (18.77)     54 (20.69)     78 (29.89)        261

  Age\                           34.92 + 1.22    37.81 + 1.52   37.50 + 1.46   41.20 + 1.02^3^   409
  (mean years + SE)                                                                              

  Race                                                                                           

   Caucasian                     45 (22.96)      39 (19.90)     37 (18.88)     75 (38.27)        196

   Non-Caucasian                 62 (29.11)      36 (16.90)     52 (24.41)     63 (29.58)        213

  Maternal education\            2.39 + 0.06     2.39 + 0.09    2.25 + 0.08    2.44 + 0.07       409
  (mean years + SE)                                                                              

  Cigarette smoker               64 (26.02)      49 (19.92)     56 (22.76)     77 (31.30)        246

  Medications                                                                                    

   Aripiprazole                  9 (19.57)       5 (10.87)      12 (26.09)     20 (43.48)        46

   Clozapine                     12 (19.05)      12 (19.05)     12 (19.05)     27 (42.86)        63

   Olanzapine                    24 (33.80)      16 (22.54)     13 (18.31)     18 (23.35)        71

   Quetiapine                    10 (20.83)      10 (20.83)     7 (14.58)      21 (43.75)        48

   Risperidone                   31 (28.44)      23 (21.10)     24 (22.02)     31 (28.44)        109

   Ziprasidone                   5 (22.73)       4 (18.18)      4 (18.18)      9 (40.91)         22

   Anticholinergics              33 (21.85)      32 (21.19)     36 (23.84)     50 (33.11)        151

   Antibiotics                   2 (22.22)       5 (55.56)      0 (0.00)       2 (22.22)         9

  Comorbid GI condition^4^                                                                       

   GERD                          0 (0.00)        34 (28.33)     0 (0.00)       86 (71.67)        120

   Constipation                  0 (0.00)        26 (30.23)     0 (0.00)       60 (69.77)        86

   Diarrhea                      0 (0.00)        4 (15.38)      0 (0.00)       22 (84.62)        26

  Comorbid endocrine condition                                                                   

   Obesity                       0 (0.00)        0 (0.00)       62 (40.00)     93 (60.00)        155

   Diabetes                      0 (0.00)        0 (0.00)       21 (33.33)     42 (66.67)        63

   Thyroid                       0 (0.00)        0 (0.00)       3 (9.09)       30 (90.91)        33

   Body mass index\              25.2 + 0.39     25.75 + 0.48   32.79 + 0.69   34.69 + 0.68      386^5^
  (mean score + SE)                                                                              
  -------------------------------------------------------------------------------------------------------

^1^Gastrointestinal (GI), Endocrine (Endoc), Negative (−), Positive (+).

^2^Female vs male differences among groups. Refer to text for details. Females were more likely to have both conditions and males neither: chi-square = 9.19, p \< 0.03.

^3^Participants with both conditions were older than those who had neither: ANOVA, F = 5.00, p \< 0.001.

^4^Comorbid conditions are listed for descriptive purposes only; prevalence is expected to vary between groups.

^5^Data not available for complete sample of 409.

Biomarker Levels as Continuous Variables {#s3_2}
----------------------------------------

Plasma levels of six biomarkers typically used as measures of GI and systemic inflammation were quantified, and differences relative to the non-GI/non-endocrine group are depicted in [**Table 3**](#T3){ref-type="table"}. Plasma levels of the general biomarker of inflammation, CRP, were significantly elevated in the GI−/endocrine+ and GI+/endocrine+ groups compared to the group without these conditions (ANOVA, F = 8.99, p \< 0.0001). Plasma levels of LBP were significantly elevated in the GI−/endocrine+ and GI+/endocrine+ groups compared to the GI−/endocrine-free (ANOVA, F = 7.74, p \< 0.0001). IgG antibody levels directed against the yeast *S. cerevisiae* and against the food antigens, bovine milk casein and wheat gluten, were elevated in the GI+/endocrine− groups with some variation according to sex as shown in [**Table 3**](#T3){ref-type="table"}. Antibody levels directed against the food antigens were also elevated in the GI−/endocrine+ and GI+/endocrine+ groups, again with some variation as shown in [**Table 3**](#T3){ref-type="table"}. Plasma levels of sCD14 were not significantly different between groups.

###### 

Comparison of biomarker levels by sex and by GI and endocrine comorbidity status.

  Biomarker                                 GI+/Endoc−   GI−/Endoc+    GI+/Endoc+
  -------------------------------- -------- ------------ ------------- -------------
  C-Reactive Protein               All      NS           p \< 0.0002   p \< 0.0001
                                   Female   NS           p \< 0.03     p \< 0.005
                                   Male     p \< 0.03    p \< 0.002    p \< 0.0003
  LPS-Binding Protein              All      NS           p \< 0.001    p \< 0.0001
                                   Female   NS           p \< 0.007    p \< 0.005
                                   Male     NS           p \< 0.03     p \< 0.001
  Soluble CD14                     All      NS           NS            NS
                                   Female   NS           NS            NS
                                   Male     NS           NS            NS
  *Saccharomyces cerevisiae* IgG   All      p \< 0.02    NS            NS
                                   Female   NS           NS            NS
                                   Male     p \< 0.02    NS            NS
  Bovine Casein IgG                All      NS           NS            NS
                                   Female   NS           NS            NS
                                   Male     p \< 0.04    p \< 0.03     ns
  Wheat Gluten IgG                 All      p \< 0.03    p \< 0.02     p \< 0.03
                                   Female   NS           NS            NS
                                   Male     NS           p \< 0.005    p \< 0.01

GI−/Endoc− is the comparison group. P-values were generated from T-tests so that results are comparable across groups and biomarkers. CRP and LBP were additionally significant following ANOVAs and multivariate comparisons and are reported in the main text and [**Figure 1**](#f1){ref-type="fig"}.

Biomarker Positivity as Categorical Variables in Multivariate Models {#s3_3}
--------------------------------------------------------------------

As described above, the strongest associations of biomarker levels with the GI/endocrine groups were found for CRP and LBP. Thus, we tested whether or not the GI and endocrine conditions were interactive in multivariate logistic regression models that included age, sex, race, cigarette smoking, maternal education, and the interactive GI/endocrine variable. Relative levels of these biomarkers among GI/endocrine groups are depicted in [**Figure 1**](#f1){ref-type="fig"}. While neither GI nor endocrine disturbances were individually associated with LBP in multivariate models, GI and endocrine conditions were additive for associations with LBP positivity ([**Figure 1A**](#f1){ref-type="fig"}: GI+/endocrine+, OR = 2.32, 95^th^% CI 1.05--5.13, p \< 0.03). In contrast, GI and endocrine disturbances were not additive for CRP, but significant associations with CRP positivity were driven by endocrine disturbances ([**Figure 1B**](#f1){ref-type="fig"}: endocrine only, OR = 3.64, 95th% CI 1.35--9.84, p \< 0.05). For comparison, IgG antibodies to *S. cerevisiae* are included in [**Figure 1**](#f1){ref-type="fig"} to illustrate the patterns of a biomarker that putatively reflect only GI-based disturbances ([**Figure 1C**](#f1){ref-type="fig"}). This *S. cerevisiae* IgG association was not statistically significant in the multivariate models.

![Biomarker levels for LBP **(A)**, CRP **(B)** and ASCA **(C)** are shown. Significant differences in levels from univariate comparisons are marked with an asterisk (\*) for all members, with a pound sign (\#) for females and a plus (+) for males. Data for multivariate comparisons were significant for LBP and CRP. Significant odds ratios (OR) and 95^th^% confidence interval (CI) are shown for LBP and CRP. LBP associations were a function of both GI and endocrine disturbances, CRP of endocrine only, and ASCA of only GI disturbances.](fpsyt-11-00549-g001){#f1}

### Contribution of Specific GI and Endocrine Conditions to Biomarker Associations {#s3_3_1}

As shown in [**Table 1**](#T1){ref-type="table"}, the three most prevalent GI conditions in this schizophrenia population were GERD (41.24%), constipation (29.55%), and diarrhea (8.93%). The three most prevalent endocrine conditions were obesity (58.05%), diabetes (23.60%), and thyroid problems (12.36%). The prevalence of these conditions within the broader GI and endocrine groups is listed in [**Table 2**](#T2){ref-type="table"}. Body mass index was elevated in the endocrine positive groups compared to those who had neither GI nor endocrine conditions (ANOVA, F = 62.06, p \< 0.0001). Associations of biomarker levels as continuous variables with specific GI and endocrine conditions are depicted in [**Table 4**](#T4){ref-type="table"}. For GI variables, individuals with GERD had significantly elevated levels of CRP (p \< 0.0003), LBP (p \< 0.0002) and sCD14 (p \< 0.004) compared to those without GERD. For people with constipation, only wheat gluten IgG levels were significantly elevated compared to those without constipation (p \< 0.03). Levels of LBP (p \< 0.02), sCD14 (p \< 0.02) and *S. cerevisiae* IgG levels (p \< 0.04) were all elevated in individuals with diarrhea compared to those without. For the endocrine variables, LBP was elevated in individuals who were obese (p \< 0.0001), had diabetes (p \< 0.01) or thyroid problems (p \< 0.04) compared to those who did not have these conditions. CRP levels were elevated in those who were obese (p \< 0.0001) or who had diabetes (p \< 0.03). In individuals who had thyroid problems, wheat gluten IgG levels were elevated (p \< 0.03).

###### 

Associations of biomarkers with specific GI and endocrine conditions.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GI conditions                            GERD-          GERD+          p-value       Constipation-   Constipation+   p-value       Diarrhea-      Diarrhea+      p-value
  -------------------------------- ------- -------------- -------------- ------------- --------------- --------------- ------------- -------------- -------------- -------------
                                   n       289            120                          323             86                            383            26             

  C-Reactive Protein               Mean\   1.09\          1.45\          p \< 0.0003   1.16\           1.33\           NS            1.19\          1.33\          NS
                                   + SE    + 0.06         + 0.08                       + 0.06          + 0.10                        + 0.05         + 0.14         

  LPS-Binding Protein              Mean\   10.64\         15.00\         p \< 0.0002   11.57\          13.2\           NS            11.63\         16.14\         p \< 0.02
                                   + SE    + 0.56         + 1.27                       + 0.59          + 1.42                        + 0.55         + 2.95         

  Soluble CD14                     Mean\   1.29\          1.85\          p \< 0.004    1.42\           1.56\           NS            1.40\          2.26\          p \< 0.02
                                   + SE    + 0.11         + 0.20                       + 0.11          + 0.23                        + 0.10         + 0.42         

  *Saccharomyces cerevisiae* IgG   Mean\   1.04\          1.19\          NS            1.05\           1.22\           NS            1.06\          1.43\          p \< 0.04
                                   + SE    + 0.06         + 0.11                       + 0.06          + 0.13                        + 0.05         + 0.27         

  Bovine Casein IgG                Mean\   1.01\          0.96\          NS            1.02\           0.90\           NS            0.99\          1.15\          NS
                                   + SE    + 0.06         + 0.10                       + 0.06          + 0.10                        + 0.05         + 0.25         

  Wheat Gluten IgG                 Mean\   1.00\          0.97\          NS            0.94\           1.19\           p \< 0.03     1.00\          0.89\          NS
                                   + SE    + 0.07         + 0.10                       + 0.06          + 0.13                        + 0.06         + 0.09         

                                                                                                                                                                   

  **Endocrine conditions**                 **Obesity−**   **Obesity+**   **p-value**   **Diabetes−**   **Diabetes+**   **p-value**   **Thyroid−**   **Thyroid+**   **p-value**

                                   n       254            155                          346             63                            376            33             

  C-Reactive Protein               Mean\   0.96\          1.58\          p \< 0.0001   1.16\           1.41\           p \< 0.03     1.19\          1.30\          NS
                                   + SE    + 0.05         + 0.09                       + 0.05          + 0.12                        + 0.05         + 0.13         

  LPS-Binding Protein              Mean\   9.95\          15.14\         p \< 0.0001   11.40\          14.75\          p \< 0.01     11.63\         15.21\         p \< 0.04
                                   + SE    + 0.60         + 1.04                       + 0.59          + 1.50                        + 0.56         + 2.56         

  Soluble CD14                     Mean\   1.28\          1.74\          p \< 0.01     1.47\           1.38\           NS            1.43\          1.75\          NS
                                   + SE    + 0.11         + 0.18                       + 0.11          + 0.21                        + 0.10         + 0.44         

  *Saccharomyces cerevisiae* IgG   Mean\   1.13\          1.01\          NS            1.10\           0.98\           NS            1.08\          1.13\          NS
                                   + SE    + 0.07         + 0.08                       + 0.06          + 0.12                        + 0.05         + 0.22         

  Bovine Casein IgG                Mean\   0.98\          1.03\          NS            1.00\           0.96\           NS            0.99\          1.04\          NS
                                   + SE    + 0.06         + 0.09                       + 0.06          + 0.133                       + 0.05         + 0.18         

  Wheat Gluten IgG                 Mean\   0.95\          1.05\          NS            1.01\           0.89\           NS            0.96\          1.35\          p \< 0.03
                                   + SE    + 0.06         + 0.11                       + 0.06          + 0.08                        + 0.05         + 0.36         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Negative (−), Positive (+).

P-values were generated from T-tests.

We then used multivariate models to detect interactions of specific GI and endocrine conditions with the biomarkers. We found that the earlier interactive associations of the broadly grouped conditions were largely driven by the GI variable, GERD, and the endocrine variable, obesity. For example, LBP was independently associated with both GERD and obesity (GERD: OR = 2.42, 95th% CI 0.99--5.95, p \< 0.05; Obesity: OR = 3.40, 95th% CI 1.58--7.31--31.71, p \< 0.002), as well as to the additive interaction of these terms (OR = 4.64, 95th% CI 2.03--10.65, p \< 0.001). Further, LBP was independently associated with diarrhea (OR = 7.99, 95th% CI 2.01--31.71, p \< 0.003), but this term did not interact with obesity or other endocrine variables. CRP was strongly associated with obesity (OR = 5.36, 95th% CI 2.45--11.73, p \< 0.002) but not to an interaction of obesity with GERD. We also found that the interaction of the GI variable, constipation, with the endocrine variable, thyroid problems, was significantly associated with gluten antibody positivity (OR = 167.34, 95^th^% CI 2.58--10,836.33, p \< 0.016). Neither variable alone was associated with these gluten antibodies.

Cognitive Functioning and Psychiatric Symptoms {#s3_4}
----------------------------------------------

Finally, we evaluated the association between the GI and endocrine groups and the level of cognitive functioning and psychiatric symptom severity based on scores from RBANS and PANSS modules. Higher scores on the PANSS total symptom score and the PANSS positive symptom score were found for the GI+/endocrine− group compared to the GI−/endocrine− group (T-test t range = −2.30 to −1.81, p-value range \<0.01--0.04; [**Table 5**](#T5){ref-type="table"}). Specific GI or endocrine conditions were not significantly associated with PANSS scores. There were no significant differences in RBANS scores among the broader GI and endocrine groups; however, lower scores were observed for those who were GERD positive compared to those who were GERD negative (T-test t = 1.81, p \< 0.04).

###### 

Cognitive and psychiatric symptom scores according to gut and endocrine conditions.

  ---------------------------------------------------------------------------------------------------------------
                   GI−/Endoc−\    GI+/Endoc−\       p-value     GI−/Endoc+\    p-value   GI+/Endoc+\    p-value
                   Score + SE     Score + SE                    Score + SE               Score + SE     
  ---------------- -------------- ----------------- ----------- -------------- --------- -------------- ---------
  PANSS^1^ Total   76.57 + 1.33   80.31 + 1.57^3^   p \< 0.04   77.47 + 1.47   NS        77.26 + 1.16   NS

  Positive         18.99 + 0.48   20.73 + 0.60^4^   p \< 0.01   19.63 + 0.56   NS        19.95 + 0.46   NS

  Negative         21.48 + 0.51   21.17 + 0.38      NS          21.28 + 0.48   NS        20.38 + 0.37   NS

  RBANS^2^         64.54 + 1.20   65.07 + 1.38      NS          64.47 + 1.26   NS        64.82 + 0.98   NS
  ---------------------------------------------------------------------------------------------------------------

^1^PANSS refers to the Positive and Negative Syndrome Scale.

^2^RBANS refers to the Repeatable Battery for the Assessment of Neuropsychological Status.

^3^GI−/Endoc− is the comparison group; T-test t value = −1.81, p \< 0.04.

^4^T-test t value = −2.30, p \< 0.01.

Discussion {#s4}
==========

In this clinical study of inflammatory biomarkers, we found significant interplay between GI and endocrine systems in schizophrenia and no single biomarker reflected a sole GI or endocrine affinity, with the possible exception of *S. cerevisiae* antibodies with GI conditions. The most robust associations were found for LBP and CRP. We found that the presence of both GI and endocrine conditions was additive for the marker, LBP, and these associations were particularly evident when the broader categories of GI and endocrine disorders were broken down into specific conditions such as GERD and obesity. Plasma LBP has been traditionally considered as a marker of bacterial translocation which specifically detects and binds any circulating bacterial-derived LPS endotoxin. LBP associations with endocrine conditions suggest its modulation by hormonal and metabolic factors such as obesity, diabetes and thyroid dysfunction. Indeed, the gut microbiome and its metabolic products, some of which are hormonal, are thought to mediate behavioral responses in part through interactions with neuroendocrine pathways that link the gut and central nervous system ([@B35], [@B36]).

We found a significant association between CRP, a general marker for inflammation, primarily with endocrine conditions and to a lesser extent in univariate models with GI conditions. Antibodies directed against the dietary yeast, *S. cerevisiae*, represented the only biomarker that was associated exclusively with a GI condition. Thus, results from this study support that antibodies to *S. cerevisiae*, a marker elevated in inflammatory bowel diseases ([@B18]), may be in fact a specific measure of perturbed GI conditions. Even antibodies directed against the food antigens were associated with both GI and endocrine conditions with some variations according to sex. Interestingly, the interaction of constipation and thyroid problems was significantly associated with antibodies to wheat gluten. The other marker of bacterial translocation, sCD14, showed few significant differences in levels among GI/endocrine groups suggesting an alternative mechanism to explain its associations with schizophrenia, perhaps related to monocyte activation ([@B17]). Although sCD14 and LBP markers showed a low level of correlation in our study (data not shown), the lack of corresponding GI and endocrine group differences for sCD14 further supports its role in inflammatory pathways that do not necessarily impact LBP.

More severe psychiatric symptoms, and particularly positive symptoms, were significantly associated with GI and not endocrine conditions. Studies of the gut--brain axis increasingly demonstrate a role for the microbiome and downstream pathological effects related to inflammation when this microbial community is in dysbiosis. In schizophrenia, case--control differences in the blood biomarkers examined here suggest that a low-grade peripheral inflammation is related to the translocation of gut-based microbes and metabolic products across compromised gut-associated vascular barriers into systemic circulation. This low-grade systemic inflammation, in turn, is thought to produce similar permeability at the blood-brain barrier, thus providing a mechanism by which gut-based products might enter the central nervous system and alter brain functioning ([@B4], [@B37], [@B38]).

The extent to which our results can be extrapolated is limited by several factors. This study is cross-sectional which prevents us from knowing if levels of these markers fluctuate over time or from making cause and effect interpretations. Furthermore, our control group comparison upon which seropositivities were designated may have included individuals with GI or endocrine conditions; thus, seropositivity cut-offs may be over-estimated and associated with a possible increase in false-negatives in the case group. Our subgroup stratification reduces the power of some of the statistical comparisons, particularly between and among the female and male groupings and between the less prevalent GI and endocrine conditions; however, promising associations are present, as evident by the data in [**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}. It is also possible that certain GI and endocrine conditions are underreported or are not documented in the medical record and thus not detected during study enrollment. Furthermore, the effect of medication on these markers is not known, although there were no significant differences in the use of specific therapeutics among the four GI and endocrine categories in this study. Also, previous studies in antipsychotic-naïve cohorts indicated that differences in marker levels between groups were not a function of medication ([@B30], [@B31]). However, other unidentified environmental or other confounders may contribute to these findings.

Our results indicate that the relationships between GI, endocrine and immune systems in schizophrenia are complex. It is possible that co-existing GI and endocrine pathologies in people with psychiatric disorders further compound inflammation and dysregulation of immune pathways, some of which may impact the brain. Understanding the biochemical mechanisms of how these imbalances in peripheral systems relate to cognitive deficits and psychiatric symptoms may lead to new strategies to more effectively prevent and treat these disorders.
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